Association of a single nucleotide polymorphism in the C-reactive protein gene (-286) with susceptibility to

Hayder A Giha1, Amre Nasr, Mattias Ekström

  • 1Department of Medical Biochemistry, Faculty of Medicine and Medical Sciences, Arabian Gulf University, Manama, Kingdom of Bahrain. gehaha2002@yahoo.com

Insights

The CRP -286 A-allele is linked to higher malaria susceptibility in Sudanese individuals. This genetic factor correlates with more frequent malaria episodes and increased parasite counts, impacting host immunity.

Area of Science:

  • Immunogenetics
  • Infectious Disease Epidemiology
  • Molecular Biology

Background:

  • Inflammation's role in malaria pathogenesis is unclear.
  • C-reactive protein (CRP) may negatively impact host immunity.
  • A CRP gene polymorphism (-286, C>T>A) influences CRP levels.

Purpose of the Study:

  • To investigate the association between the CRP -286 polymorphism and malaria susceptibility.
  • To determine if CRP alleles influence the number of malaria episodes and parasite counts.

Main Methods:

  • Genotyping of the CRP -286 locus using pyrosequencing in 192 Sudanese donors.
  • Longitudinal follow-up for malaria infection over 9 years.
  • Malaria episodes and parasite counts used as measures of susceptibility.

Main Results:

  • The CRP -286 A-allele was significantly associated with an increased number of malaria episodes (P = 0.007).
  • A-allele carriers showed a higher proportion of individuals with multiple malaria episodes (43% for 1-4, 63% for >=5) compared to non-carriers (18%) (P = 0.002).
  • The A-allele was also linked to higher parasite counts.

Conclusions:

  • The CRP -286 A-allele is associated with increased susceptibility to uncomplicated Plasmodium falciparum malaria.
  • This genetic variation may play a role in modulating host immune response to malaria infections.

Related Concept Videos

Malaria01:29

Malaria

Malaria pathogenesis in humans reflects a delicate interplay between parasite biology and host response. Clinical illness reflects a host’s immune response to the parasite’s asexual replication cycle, which is often asymptomatic in individuals with partial immunity. From the parasite's perspective, transmission between mosquito and human with minimal host pathology is evolutionarily advantageous. Among the six Plasmodium species infecting humans, P. falciparum and P. vivax dominate in global...
Single Nucleotide Polymorphisms-SNPs01:05

Single Nucleotide Polymorphisms-SNPs

A single nucleotide polymorphism or SNP is a single nucleotide variation at a specific genomic position in a large population. It is the most prevalent type of sequence variation found in the human genome. Point mutations that occur in more than 1% of the population qualify as SNPs. These are present once every 1000 nucleotides on an average in the human genome. Replacement of a purine with another purine (A/G) or a pyrimidine with another pyrimidine (C/T) is known as a transition. In contrast,...
Genome-wide Association Studies-GWAS01:11

Genome-wide Association Studies-GWAS

Genome-wide association studies or GWAS are used to identify whether common SNPs are associated with certain diseases. Suppose specific SNPs are more frequently observed in individuals with a particular disease than those without the disease. In that case, those SNPs are said to be associated with the disease. Chi-square analysis is performed to check the probability of the allele likely to be associated with the disease.
GWAS does not require the identification of the target gene involved in...
Pharmacogenetic Phenotypes: Alterations in Pharmacokinetics, Drug Targets and Biologic Milieu01:29

Pharmacogenetic Phenotypes: Alterations in Pharmacokinetics, Drug Targets and Biologic Milieu

Genetic variations significantly influence drug response through pharmacokinetics, receptor interactions, and biologic milieu modifications. Pharmacokinetic alterations impact drug metabolism and clearance, affecting efficacy and toxicity. Variants in drug-metabolizing enzymes, such as CYP2C9 and CYP2C19, alter drug activation and elimination. For example, CYP2C9 loss-of-function variants require lower warfarin doses to prevent excessive bleeding, while CYP2C19 variants reduce clopidogrel...
Pharmacogenomics: Identification of New Drug Targets01:29

Pharmacogenomics: Identification of New Drug Targets

Advances in genomics have profoundly influenced drug discovery by increasing both the speed and accuracy of pharmaceutical development. Pharmacogenomics, which examines how genetic variation influences drug response, facilitates the identification of novel therapeutic targets and enables patient stratification for personalized treatment. These strategies contribute to improved drug efficacy, minimized adverse effects, and more efficient clinical trial design.Mapping genetic differences...
Comparing Copy Number Variations and SNPs02:26

Comparing Copy Number Variations and SNPs

Sequencing of the human genome has opened up several best-kept secrets of the genome. Scientists have identified thousands of genome variations that exist within a population. These variations can be a single nucleotide or a larger chromosomal variation.
Copy number variations or CNVs are the structural variations that cover more than 1kb of DNA sequence. The single nucleotide polymorphism (SNP), on the other hand, is a single nucleotide change or a point mutation that is found in more than 1%...